human mab antibody Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93
    Diaclone anti ifn γ mabs
    C57BL/6 mice were injected i.v. with PBS, 106 TUs IDLV-OVA or OVA/CpG. (A-B) Seven days later, anti-OVA CTL responses were assessed by an in vivo killing assay (A) and <t>IFN-γ</t> ELISPOT (B). (C-D) The persistence of the anti-OVA CTL responses was assessed by an in vivo killing assay (C) and IFN-γ ELISPOT (D) up to 6 months after immunization. (A-D) The results are expressed as the percentage of specific lysis for the in vivo killing assay (A, C) and IFN-γ spot-forming cells (SFC) per 106 splenocytes for ELISPOT (B, D). Each dot represents an individual mouse. The results represent the means ± SEM of cumulative data from 33 mice from eleven independent experiments (A, B) or from 6 mice from two independent experiments (C, D). (E-G) Seven days and one month later, the OVA-specific CD8+ T cell response was analyzed by H-2Kb/SIINFEKL-Dextramer staining. The gating strategy for CD3+ CD8+ CD4− dextramer positive cells 1 week after immunization is shown in (E). (F) The percentage of CD3+ CD8+ dextramer+ cells among the total CD8+ cells is shown at 1 week and 1 month after immunization. The results represent the means ± SEM of cumulative data from 8 to 9 mice from three independent experiments. (G) Expression of CD27, CD44, CD45RA, CD62L and CCR7 by CD3+ CD8+ dextramer+ cells. The results are expressed as the fold-increase in the mean fluorescence intensity (MFI) ± SEM compared to PBS-injected mice and represent the cumulative data from 8 to 9 mice from three independent experiments. Statistical analysis was performed by unpaired Student’s t-test (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). (H, I, J) Seven days later, splenic CD8+ T cells were purified from PBS, IDLV-OVA and OVA/CpG treated mice, whereas OVA-specific CD8+ T cells (H-2Kb/SIINFEKL-Dextramer+ CD8+) were purified from IDLV-OVA and OVA/CpG immunized mice. RNA was extracted, and the expression of genes involved in the immune response was assessed with the nCounter Mouse Pan Cancer Immune Profiling Panel. (H) Heat Map of genes significantly and differentially expressed by OVA-specific CD8+ T cells purified from IDLV-OVA or OVA/CpG immunized mice (IDLV-OVA Dext and OVA/CpG Dext, respectively) compared to CD8+ T cells purified from PBS-injected mice (PBS). (I) PCA (Principal Component Analysis) of genes significantly and differentially expressed by OVA-specific CD8+ T cells purified from IDLV-OVA or OVA/CpG immunized mice (IDLV-OVA Dext and OVA/CpG Dext, respectively) compared to CD8+ T cells purified from mice injected with PBS (PBS) or IDLV-OVA (IDLV-OVA) or OVA/CpG (OVA/CpG). (J) Venn diagrams of upregulated (left panel) and downregulated (right panel) genes differentially expressed by IDLV-OVA Dext or OVA/CpG Dext. The results represent the cumulative data from 4 to 5 mice from five independent experiments. See also Figures S1 and S2.
    Anti Ifn γ Mabs, supplied by Diaclone, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti ifn γ mabs/product/Diaclone
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti ifn γ mabs - by Bioz Stars, 2024-02
    93/100 stars
      Buy from Supplier

    88
    Cayman Chemical mouse anti human cox 2 ab
    C57BL/6 mice were injected i.v. with PBS, 106 TUs IDLV-OVA or OVA/CpG. (A-B) Seven days later, anti-OVA CTL responses were assessed by an in vivo killing assay (A) and <t>IFN-γ</t> ELISPOT (B). (C-D) The persistence of the anti-OVA CTL responses was assessed by an in vivo killing assay (C) and IFN-γ ELISPOT (D) up to 6 months after immunization. (A-D) The results are expressed as the percentage of specific lysis for the in vivo killing assay (A, C) and IFN-γ spot-forming cells (SFC) per 106 splenocytes for ELISPOT (B, D). Each dot represents an individual mouse. The results represent the means ± SEM of cumulative data from 33 mice from eleven independent experiments (A, B) or from 6 mice from two independent experiments (C, D). (E-G) Seven days and one month later, the OVA-specific CD8+ T cell response was analyzed by H-2Kb/SIINFEKL-Dextramer staining. The gating strategy for CD3+ CD8+ CD4− dextramer positive cells 1 week after immunization is shown in (E). (F) The percentage of CD3+ CD8+ dextramer+ cells among the total CD8+ cells is shown at 1 week and 1 month after immunization. The results represent the means ± SEM of cumulative data from 8 to 9 mice from three independent experiments. (G) Expression of CD27, CD44, CD45RA, CD62L and CCR7 by CD3+ CD8+ dextramer+ cells. The results are expressed as the fold-increase in the mean fluorescence intensity (MFI) ± SEM compared to PBS-injected mice and represent the cumulative data from 8 to 9 mice from three independent experiments. Statistical analysis was performed by unpaired Student’s t-test (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). (H, I, J) Seven days later, splenic CD8+ T cells were purified from PBS, IDLV-OVA and OVA/CpG treated mice, whereas OVA-specific CD8+ T cells (H-2Kb/SIINFEKL-Dextramer+ CD8+) were purified from IDLV-OVA and OVA/CpG immunized mice. RNA was extracted, and the expression of genes involved in the immune response was assessed with the nCounter Mouse Pan Cancer Immune Profiling Panel. (H) Heat Map of genes significantly and differentially expressed by OVA-specific CD8+ T cells purified from IDLV-OVA or OVA/CpG immunized mice (IDLV-OVA Dext and OVA/CpG Dext, respectively) compared to CD8+ T cells purified from PBS-injected mice (PBS). (I) PCA (Principal Component Analysis) of genes significantly and differentially expressed by OVA-specific CD8+ T cells purified from IDLV-OVA or OVA/CpG immunized mice (IDLV-OVA Dext and OVA/CpG Dext, respectively) compared to CD8+ T cells purified from mice injected with PBS (PBS) or IDLV-OVA (IDLV-OVA) or OVA/CpG (OVA/CpG). (J) Venn diagrams of upregulated (left panel) and downregulated (right panel) genes differentially expressed by IDLV-OVA Dext or OVA/CpG Dext. The results represent the cumulative data from 4 to 5 mice from five independent experiments. See also Figures S1 and S2.
    Mouse Anti Human Cox 2 Ab, supplied by Cayman Chemical, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mouse anti human cox 2 ab/product/Cayman Chemical
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mouse anti human cox 2 ab - by Bioz Stars, 2024-02
    88/100 stars
      Buy from Supplier

    93
    Diaclone anti human cd28 mab
    C57BL/6 mice were injected i.v. with PBS, 106 TUs IDLV-OVA or OVA/CpG. (A-B) Seven days later, anti-OVA CTL responses were assessed by an in vivo killing assay (A) and <t>IFN-γ</t> ELISPOT (B). (C-D) The persistence of the anti-OVA CTL responses was assessed by an in vivo killing assay (C) and IFN-γ ELISPOT (D) up to 6 months after immunization. (A-D) The results are expressed as the percentage of specific lysis for the in vivo killing assay (A, C) and IFN-γ spot-forming cells (SFC) per 106 splenocytes for ELISPOT (B, D). Each dot represents an individual mouse. The results represent the means ± SEM of cumulative data from 33 mice from eleven independent experiments (A, B) or from 6 mice from two independent experiments (C, D). (E-G) Seven days and one month later, the OVA-specific CD8+ T cell response was analyzed by H-2Kb/SIINFEKL-Dextramer staining. The gating strategy for CD3+ CD8+ CD4− dextramer positive cells 1 week after immunization is shown in (E). (F) The percentage of CD3+ CD8+ dextramer+ cells among the total CD8+ cells is shown at 1 week and 1 month after immunization. The results represent the means ± SEM of cumulative data from 8 to 9 mice from three independent experiments. (G) Expression of CD27, CD44, CD45RA, CD62L and CCR7 by CD3+ CD8+ dextramer+ cells. The results are expressed as the fold-increase in the mean fluorescence intensity (MFI) ± SEM compared to PBS-injected mice and represent the cumulative data from 8 to 9 mice from three independent experiments. Statistical analysis was performed by unpaired Student’s t-test (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). (H, I, J) Seven days later, splenic CD8+ T cells were purified from PBS, IDLV-OVA and OVA/CpG treated mice, whereas OVA-specific CD8+ T cells (H-2Kb/SIINFEKL-Dextramer+ CD8+) were purified from IDLV-OVA and OVA/CpG immunized mice. RNA was extracted, and the expression of genes involved in the immune response was assessed with the nCounter Mouse Pan Cancer Immune Profiling Panel. (H) Heat Map of genes significantly and differentially expressed by OVA-specific CD8+ T cells purified from IDLV-OVA or OVA/CpG immunized mice (IDLV-OVA Dext and OVA/CpG Dext, respectively) compared to CD8+ T cells purified from PBS-injected mice (PBS). (I) PCA (Principal Component Analysis) of genes significantly and differentially expressed by OVA-specific CD8+ T cells purified from IDLV-OVA or OVA/CpG immunized mice (IDLV-OVA Dext and OVA/CpG Dext, respectively) compared to CD8+ T cells purified from mice injected with PBS (PBS) or IDLV-OVA (IDLV-OVA) or OVA/CpG (OVA/CpG). (J) Venn diagrams of upregulated (left panel) and downregulated (right panel) genes differentially expressed by IDLV-OVA Dext or OVA/CpG Dext. The results represent the cumulative data from 4 to 5 mice from five independent experiments. See also Figures S1 and S2.
    Anti Human Cd28 Mab, supplied by Diaclone, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti human cd28 mab/product/Diaclone
    Average 93 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti human cd28 mab - by Bioz Stars, 2024-02
    93/100 stars
      Buy from Supplier

    92
    Diaclone abs against human cd3
    C57BL/6 mice were injected i.v. with PBS, 106 TUs IDLV-OVA or OVA/CpG. (A-B) Seven days later, anti-OVA CTL responses were assessed by an in vivo killing assay (A) and <t>IFN-γ</t> ELISPOT (B). (C-D) The persistence of the anti-OVA CTL responses was assessed by an in vivo killing assay (C) and IFN-γ ELISPOT (D) up to 6 months after immunization. (A-D) The results are expressed as the percentage of specific lysis for the in vivo killing assay (A, C) and IFN-γ spot-forming cells (SFC) per 106 splenocytes for ELISPOT (B, D). Each dot represents an individual mouse. The results represent the means ± SEM of cumulative data from 33 mice from eleven independent experiments (A, B) or from 6 mice from two independent experiments (C, D). (E-G) Seven days and one month later, the OVA-specific CD8+ T cell response was analyzed by H-2Kb/SIINFEKL-Dextramer staining. The gating strategy for CD3+ CD8+ CD4− dextramer positive cells 1 week after immunization is shown in (E). (F) The percentage of CD3+ CD8+ dextramer+ cells among the total CD8+ cells is shown at 1 week and 1 month after immunization. The results represent the means ± SEM of cumulative data from 8 to 9 mice from three independent experiments. (G) Expression of CD27, CD44, CD45RA, CD62L and CCR7 by CD3+ CD8+ dextramer+ cells. The results are expressed as the fold-increase in the mean fluorescence intensity (MFI) ± SEM compared to PBS-injected mice and represent the cumulative data from 8 to 9 mice from three independent experiments. Statistical analysis was performed by unpaired Student’s t-test (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). (H, I, J) Seven days later, splenic CD8+ T cells were purified from PBS, IDLV-OVA and OVA/CpG treated mice, whereas OVA-specific CD8+ T cells (H-2Kb/SIINFEKL-Dextramer+ CD8+) were purified from IDLV-OVA and OVA/CpG immunized mice. RNA was extracted, and the expression of genes involved in the immune response was assessed with the nCounter Mouse Pan Cancer Immune Profiling Panel. (H) Heat Map of genes significantly and differentially expressed by OVA-specific CD8+ T cells purified from IDLV-OVA or OVA/CpG immunized mice (IDLV-OVA Dext and OVA/CpG Dext, respectively) compared to CD8+ T cells purified from PBS-injected mice (PBS). (I) PCA (Principal Component Analysis) of genes significantly and differentially expressed by OVA-specific CD8+ T cells purified from IDLV-OVA or OVA/CpG immunized mice (IDLV-OVA Dext and OVA/CpG Dext, respectively) compared to CD8+ T cells purified from mice injected with PBS (PBS) or IDLV-OVA (IDLV-OVA) or OVA/CpG (OVA/CpG). (J) Venn diagrams of upregulated (left panel) and downregulated (right panel) genes differentially expressed by IDLV-OVA Dext or OVA/CpG Dext. The results represent the cumulative data from 4 to 5 mice from five independent experiments. See also Figures S1 and S2.
    Abs Against Human Cd3, supplied by Diaclone, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/abs against human cd3/product/Diaclone
    Average 92 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    abs against human cd3 - by Bioz Stars, 2024-02
    92/100 stars
      Buy from Supplier

    85
    Diaclone anti cd45ro fitc
    C57BL/6 mice were injected i.v. with PBS, 106 TUs IDLV-OVA or OVA/CpG. (A-B) Seven days later, anti-OVA CTL responses were assessed by an in vivo killing assay (A) and <t>IFN-γ</t> ELISPOT (B). (C-D) The persistence of the anti-OVA CTL responses was assessed by an in vivo killing assay (C) and IFN-γ ELISPOT (D) up to 6 months after immunization. (A-D) The results are expressed as the percentage of specific lysis for the in vivo killing assay (A, C) and IFN-γ spot-forming cells (SFC) per 106 splenocytes for ELISPOT (B, D). Each dot represents an individual mouse. The results represent the means ± SEM of cumulative data from 33 mice from eleven independent experiments (A, B) or from 6 mice from two independent experiments (C, D). (E-G) Seven days and one month later, the OVA-specific CD8+ T cell response was analyzed by H-2Kb/SIINFEKL-Dextramer staining. The gating strategy for CD3+ CD8+ CD4− dextramer positive cells 1 week after immunization is shown in (E). (F) The percentage of CD3+ CD8+ dextramer+ cells among the total CD8+ cells is shown at 1 week and 1 month after immunization. The results represent the means ± SEM of cumulative data from 8 to 9 mice from three independent experiments. (G) Expression of CD27, CD44, CD45RA, CD62L and CCR7 by CD3+ CD8+ dextramer+ cells. The results are expressed as the fold-increase in the mean fluorescence intensity (MFI) ± SEM compared to PBS-injected mice and represent the cumulative data from 8 to 9 mice from three independent experiments. Statistical analysis was performed by unpaired Student’s t-test (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). (H, I, J) Seven days later, splenic CD8+ T cells were purified from PBS, IDLV-OVA and OVA/CpG treated mice, whereas OVA-specific CD8+ T cells (H-2Kb/SIINFEKL-Dextramer+ CD8+) were purified from IDLV-OVA and OVA/CpG immunized mice. RNA was extracted, and the expression of genes involved in the immune response was assessed with the nCounter Mouse Pan Cancer Immune Profiling Panel. (H) Heat Map of genes significantly and differentially expressed by OVA-specific CD8+ T cells purified from IDLV-OVA or OVA/CpG immunized mice (IDLV-OVA Dext and OVA/CpG Dext, respectively) compared to CD8+ T cells purified from PBS-injected mice (PBS). (I) PCA (Principal Component Analysis) of genes significantly and differentially expressed by OVA-specific CD8+ T cells purified from IDLV-OVA or OVA/CpG immunized mice (IDLV-OVA Dext and OVA/CpG Dext, respectively) compared to CD8+ T cells purified from mice injected with PBS (PBS) or IDLV-OVA (IDLV-OVA) or OVA/CpG (OVA/CpG). (J) Venn diagrams of upregulated (left panel) and downregulated (right panel) genes differentially expressed by IDLV-OVA Dext or OVA/CpG Dext. The results represent the cumulative data from 4 to 5 mice from five independent experiments. See also Figures S1 and S2.
    Anti Cd45ro Fitc, supplied by Diaclone, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd45ro fitc/product/Diaclone
    Average 85 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti cd45ro fitc - by Bioz Stars, 2024-02
    85/100 stars
      Buy from Supplier

    Image Search Results


    C57BL/6 mice were injected i.v. with PBS, 106 TUs IDLV-OVA or OVA/CpG. (A-B) Seven days later, anti-OVA CTL responses were assessed by an in vivo killing assay (A) and IFN-γ ELISPOT (B). (C-D) The persistence of the anti-OVA CTL responses was assessed by an in vivo killing assay (C) and IFN-γ ELISPOT (D) up to 6 months after immunization. (A-D) The results are expressed as the percentage of specific lysis for the in vivo killing assay (A, C) and IFN-γ spot-forming cells (SFC) per 106 splenocytes for ELISPOT (B, D). Each dot represents an individual mouse. The results represent the means ± SEM of cumulative data from 33 mice from eleven independent experiments (A, B) or from 6 mice from two independent experiments (C, D). (E-G) Seven days and one month later, the OVA-specific CD8+ T cell response was analyzed by H-2Kb/SIINFEKL-Dextramer staining. The gating strategy for CD3+ CD8+ CD4− dextramer positive cells 1 week after immunization is shown in (E). (F) The percentage of CD3+ CD8+ dextramer+ cells among the total CD8+ cells is shown at 1 week and 1 month after immunization. The results represent the means ± SEM of cumulative data from 8 to 9 mice from three independent experiments. (G) Expression of CD27, CD44, CD45RA, CD62L and CCR7 by CD3+ CD8+ dextramer+ cells. The results are expressed as the fold-increase in the mean fluorescence intensity (MFI) ± SEM compared to PBS-injected mice and represent the cumulative data from 8 to 9 mice from three independent experiments. Statistical analysis was performed by unpaired Student’s t-test (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). (H, I, J) Seven days later, splenic CD8+ T cells were purified from PBS, IDLV-OVA and OVA/CpG treated mice, whereas OVA-specific CD8+ T cells (H-2Kb/SIINFEKL-Dextramer+ CD8+) were purified from IDLV-OVA and OVA/CpG immunized mice. RNA was extracted, and the expression of genes involved in the immune response was assessed with the nCounter Mouse Pan Cancer Immune Profiling Panel. (H) Heat Map of genes significantly and differentially expressed by OVA-specific CD8+ T cells purified from IDLV-OVA or OVA/CpG immunized mice (IDLV-OVA Dext and OVA/CpG Dext, respectively) compared to CD8+ T cells purified from PBS-injected mice (PBS). (I) PCA (Principal Component Analysis) of genes significantly and differentially expressed by OVA-specific CD8+ T cells purified from IDLV-OVA or OVA/CpG immunized mice (IDLV-OVA Dext and OVA/CpG Dext, respectively) compared to CD8+ T cells purified from mice injected with PBS (PBS) or IDLV-OVA (IDLV-OVA) or OVA/CpG (OVA/CpG). (J) Venn diagrams of upregulated (left panel) and downregulated (right panel) genes differentially expressed by IDLV-OVA Dext or OVA/CpG Dext. The results represent the cumulative data from 4 to 5 mice from five independent experiments. See also Figures S1 and S2.

    Journal: Cell reports

    Article Title: Persistence of Integrase-Deficient Lentiviral Vectors correlates with the induction of STING-independent CD8 + T cell responses

    doi: 10.1016/j.celrep.2019.01.025

    Figure Lengend Snippet: C57BL/6 mice were injected i.v. with PBS, 106 TUs IDLV-OVA or OVA/CpG. (A-B) Seven days later, anti-OVA CTL responses were assessed by an in vivo killing assay (A) and IFN-γ ELISPOT (B). (C-D) The persistence of the anti-OVA CTL responses was assessed by an in vivo killing assay (C) and IFN-γ ELISPOT (D) up to 6 months after immunization. (A-D) The results are expressed as the percentage of specific lysis for the in vivo killing assay (A, C) and IFN-γ spot-forming cells (SFC) per 106 splenocytes for ELISPOT (B, D). Each dot represents an individual mouse. The results represent the means ± SEM of cumulative data from 33 mice from eleven independent experiments (A, B) or from 6 mice from two independent experiments (C, D). (E-G) Seven days and one month later, the OVA-specific CD8+ T cell response was analyzed by H-2Kb/SIINFEKL-Dextramer staining. The gating strategy for CD3+ CD8+ CD4− dextramer positive cells 1 week after immunization is shown in (E). (F) The percentage of CD3+ CD8+ dextramer+ cells among the total CD8+ cells is shown at 1 week and 1 month after immunization. The results represent the means ± SEM of cumulative data from 8 to 9 mice from three independent experiments. (G) Expression of CD27, CD44, CD45RA, CD62L and CCR7 by CD3+ CD8+ dextramer+ cells. The results are expressed as the fold-increase in the mean fluorescence intensity (MFI) ± SEM compared to PBS-injected mice and represent the cumulative data from 8 to 9 mice from three independent experiments. Statistical analysis was performed by unpaired Student’s t-test (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). (H, I, J) Seven days later, splenic CD8+ T cells were purified from PBS, IDLV-OVA and OVA/CpG treated mice, whereas OVA-specific CD8+ T cells (H-2Kb/SIINFEKL-Dextramer+ CD8+) were purified from IDLV-OVA and OVA/CpG immunized mice. RNA was extracted, and the expression of genes involved in the immune response was assessed with the nCounter Mouse Pan Cancer Immune Profiling Panel. (H) Heat Map of genes significantly and differentially expressed by OVA-specific CD8+ T cells purified from IDLV-OVA or OVA/CpG immunized mice (IDLV-OVA Dext and OVA/CpG Dext, respectively) compared to CD8+ T cells purified from PBS-injected mice (PBS). (I) PCA (Principal Component Analysis) of genes significantly and differentially expressed by OVA-specific CD8+ T cells purified from IDLV-OVA or OVA/CpG immunized mice (IDLV-OVA Dext and OVA/CpG Dext, respectively) compared to CD8+ T cells purified from mice injected with PBS (PBS) or IDLV-OVA (IDLV-OVA) or OVA/CpG (OVA/CpG). (J) Venn diagrams of upregulated (left panel) and downregulated (right panel) genes differentially expressed by IDLV-OVA Dext or OVA/CpG Dext. The results represent the cumulative data from 4 to 5 mice from five independent experiments. See also Figures S1 and S2.

    Article Snippet: Ninety-six-well Multiscreen-HA sterile plates (Millipore, Molsheim, France) were coated with purified anti-IFN-γ mAbs (Murine IFN-γ ELISpot Pair from Diaclone).

    Techniques: Injection, In Vivo, Enzyme-linked Immunospot, Lysis, Staining, Expressing, Fluorescence, Purification

    C57BL/6 and IFNAR-KO mice were injected i.v. with PBS, 106 TUs (A-B) or 5×106 TUs (C-F) IDLV-OVA or OVA/CpG (A-B) or CpG (C-F). Seven days (A) and one month (B) later, anti-OVA CTL responses were assessed by in vivo killing assay and IFN-γ ELISPOT. The results are expressed as the percentage of specific lysis for in vivo killing assay and IFN-γ SFC per 106 splenocytes for ELISPOT. Each dot represents an individual mouse. The results represent the means ± SEM of cumulative data from 9 to 12 mice from five independent experiments (A) or 5 to 6 mice from two independent experiments (B). Eighteen hours after injection, the expression of CD40, CD86 or PDC-TREM by pDCs (C, E) and cDCs (D, F) was assessed by flow cytometry. The results are represented as histograms from one representative experiment (C, D) or expressed as the fold-increases in MFI ± SEM compared to pDCs or cDCs from PBS-injected mice (E, F). They represent the cumulative data from 6 to 8 mice from three independent experiments. Statistical analysis was performed by unpaired Student’s t-test in comparison with the PBS-treated mice or between C57BL/6 and IFNAR-KO mice, as indicated by the horizontals bars (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). See also Figure S6.

    Journal: Cell reports

    Article Title: Persistence of Integrase-Deficient Lentiviral Vectors correlates with the induction of STING-independent CD8 + T cell responses

    doi: 10.1016/j.celrep.2019.01.025

    Figure Lengend Snippet: C57BL/6 and IFNAR-KO mice were injected i.v. with PBS, 106 TUs (A-B) or 5×106 TUs (C-F) IDLV-OVA or OVA/CpG (A-B) or CpG (C-F). Seven days (A) and one month (B) later, anti-OVA CTL responses were assessed by in vivo killing assay and IFN-γ ELISPOT. The results are expressed as the percentage of specific lysis for in vivo killing assay and IFN-γ SFC per 106 splenocytes for ELISPOT. Each dot represents an individual mouse. The results represent the means ± SEM of cumulative data from 9 to 12 mice from five independent experiments (A) or 5 to 6 mice from two independent experiments (B). Eighteen hours after injection, the expression of CD40, CD86 or PDC-TREM by pDCs (C, E) and cDCs (D, F) was assessed by flow cytometry. The results are represented as histograms from one representative experiment (C, D) or expressed as the fold-increases in MFI ± SEM compared to pDCs or cDCs from PBS-injected mice (E, F). They represent the cumulative data from 6 to 8 mice from three independent experiments. Statistical analysis was performed by unpaired Student’s t-test in comparison with the PBS-treated mice or between C57BL/6 and IFNAR-KO mice, as indicated by the horizontals bars (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). See also Figure S6.

    Article Snippet: Ninety-six-well Multiscreen-HA sterile plates (Millipore, Molsheim, France) were coated with purified anti-IFN-γ mAbs (Murine IFN-γ ELISpot Pair from Diaclone).

    Techniques: Injection, In Vivo, Enzyme-linked Immunospot, Lysis, Expressing, Flow Cytometry

    PBS and DT treated-BDCA2-DTR (A-C) and -CD11c-DTR → C57BL/6 chimeric mice (DF) were injected i.v. with PBS, 106 (A, D) or 5×106 TUs IDLV-OVA (B, C, E, F) or OVA/CpG (A, D) or CpG (B, C, E, F). Seven days later, anti-OVA CTL responses were assessed by in vivo killing and IFN-γ ELISPOT assays (A, D). The results are expressed as the percentage of specific lysis for CTL activity and IFN-γ SFC per 106 splenocytes for ELISPOT. Each dot represents an individual mouse. The results represent the means ± SEM of cumulative data from 6 to 8 mice collected from three independent experiments (A) or 3 to 5 mice from two independent experiments (D). Eighteen hours after injection, the expression of CD40, CD86 or PDC-TREM by cDCs (B, C) and pDCs (E, F) was assessed by flow cytometry. The results are represented as histograms from one representative experiment (B, E) or expressed as the fold-increase in MFI ± SEM compared to pDCs or cDCs from PBS-injected mice (C, F). They represent the cumulative data from 4 to 6 mice (C) or 2 to 5 mice from two independent experiments (F). Statistical analysis was performed by unpaired Student’s t-test in comparison with the PBS-treated mice or between PBS and DT treated-mice, as indicated by the horizontals bars (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). See also Figures S4 and S5.

    Journal: Cell reports

    Article Title: Persistence of Integrase-Deficient Lentiviral Vectors correlates with the induction of STING-independent CD8 + T cell responses

    doi: 10.1016/j.celrep.2019.01.025

    Figure Lengend Snippet: PBS and DT treated-BDCA2-DTR (A-C) and -CD11c-DTR → C57BL/6 chimeric mice (DF) were injected i.v. with PBS, 106 (A, D) or 5×106 TUs IDLV-OVA (B, C, E, F) or OVA/CpG (A, D) or CpG (B, C, E, F). Seven days later, anti-OVA CTL responses were assessed by in vivo killing and IFN-γ ELISPOT assays (A, D). The results are expressed as the percentage of specific lysis for CTL activity and IFN-γ SFC per 106 splenocytes for ELISPOT. Each dot represents an individual mouse. The results represent the means ± SEM of cumulative data from 6 to 8 mice collected from three independent experiments (A) or 3 to 5 mice from two independent experiments (D). Eighteen hours after injection, the expression of CD40, CD86 or PDC-TREM by cDCs (B, C) and pDCs (E, F) was assessed by flow cytometry. The results are represented as histograms from one representative experiment (B, E) or expressed as the fold-increase in MFI ± SEM compared to pDCs or cDCs from PBS-injected mice (C, F). They represent the cumulative data from 4 to 6 mice (C) or 2 to 5 mice from two independent experiments (F). Statistical analysis was performed by unpaired Student’s t-test in comparison with the PBS-treated mice or between PBS and DT treated-mice, as indicated by the horizontals bars (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). See also Figures S4 and S5.

    Article Snippet: Ninety-six-well Multiscreen-HA sterile plates (Millipore, Molsheim, France) were coated with purified anti-IFN-γ mAbs (Murine IFN-γ ELISpot Pair from Diaclone).

    Techniques: Injection, In Vivo, Enzyme-linked Immunospot, Lysis, Activity Assay, Expressing, Flow Cytometry

    C57BL/6, TLR3−/− (A), TLR4−/− (B), TLR7−/− (C), TLR9−/− (D), MyD88−/− (E), IRF3−/− (F), IRF7−/− (G) and IRF3/7−/− (H) mice were immunized i.v. with PBS, 106 TUs IDLV-OVA or OVA/CpG. Seven days later, anti-OVA CTL responses were assessed by in vivo killing assays (left panels) and IFN-γ ELISPOT assays (right panels). The results are expressed as the percentage of specific lysis for the in vivo killing assay and as the IFN-γ SFC per 106 splenocytes for ELISPOT. Each dot represents an individual mouse. The results represent the means ± SEM of cumulative data from 5 to 9 mice from two to three independent experiments. Statistical analysis was performed by an unpaired Student’s t-test in comparison with control C57BL/6 mice (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).

    Journal: Cell reports

    Article Title: Persistence of Integrase-Deficient Lentiviral Vectors correlates with the induction of STING-independent CD8 + T cell responses

    doi: 10.1016/j.celrep.2019.01.025

    Figure Lengend Snippet: C57BL/6, TLR3−/− (A), TLR4−/− (B), TLR7−/− (C), TLR9−/− (D), MyD88−/− (E), IRF3−/− (F), IRF7−/− (G) and IRF3/7−/− (H) mice were immunized i.v. with PBS, 106 TUs IDLV-OVA or OVA/CpG. Seven days later, anti-OVA CTL responses were assessed by in vivo killing assays (left panels) and IFN-γ ELISPOT assays (right panels). The results are expressed as the percentage of specific lysis for the in vivo killing assay and as the IFN-γ SFC per 106 splenocytes for ELISPOT. Each dot represents an individual mouse. The results represent the means ± SEM of cumulative data from 5 to 9 mice from two to three independent experiments. Statistical analysis was performed by an unpaired Student’s t-test in comparison with control C57BL/6 mice (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).

    Article Snippet: Ninety-six-well Multiscreen-HA sterile plates (Millipore, Molsheim, France) were coated with purified anti-IFN-γ mAbs (Murine IFN-γ ELISpot Pair from Diaclone).

    Techniques: In Vivo, Enzyme-linked Immunospot, Lysis

    (A) C57BL/6 mice were injected i.v. with PBS or 5×106 TUs IDLV-GFP. Four hours after injection, CD11c+ splenic cells were sorted, and the pathways involved in antiviral responses and NF-κB signaling were analyzed using the RT2 profiler PCR array. The results are expressed as the means ± SEM of fold regulation compared to PBS-injected mice, and represent the cumulative data from two mice from two independent experiments. The green dashed line represents a threshold of two-fold downregulation and the red dashed line represents a threshold of two-fold upregulation. C57BL/6 (B), MAVS−/− (C), STING−/− (D) and CD11c-Cre × Nemo flox (E) mice were injected i.v. with PBS, 106 TUs IDLV-OVA, OVA/5’ppp-dsRNA or OVA/CpG. Seven days (B-E) or one month (B) later, anti-OVA CTL responses were assessed by an in vivo killing assay (left panels) and IFN-γ ELISPOT (right panels). The results are expressed as the percentage of specific lysis for the in vivo killing assay and IFN-γ SFC per 106 splenocytes for ELISPOT. Each dot represents an individual mouse. The results represent the means ± SEM of cumulative data from 3 to 9 mice from two to three independent experiments (B-D) or 2 to 6 mice from two independent experiments (E). Nemo+ mice were born from the crossing of CD11c-Cre littermate non transgenic mice × Nemo flox mice. In contrast, Nemo− mice were born from the crossing of CD11c-Cre transgenic mice × Nemo flox mice. Statistical analysis was performed by unpaired Student’s t-test in comparison with PBS-treated mice or between control and deficient mice, as indicated by the horizontal bars (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). See also Figures S7, S8 and S9.

    Journal: Cell reports

    Article Title: Persistence of Integrase-Deficient Lentiviral Vectors correlates with the induction of STING-independent CD8 + T cell responses

    doi: 10.1016/j.celrep.2019.01.025

    Figure Lengend Snippet: (A) C57BL/6 mice were injected i.v. with PBS or 5×106 TUs IDLV-GFP. Four hours after injection, CD11c+ splenic cells were sorted, and the pathways involved in antiviral responses and NF-κB signaling were analyzed using the RT2 profiler PCR array. The results are expressed as the means ± SEM of fold regulation compared to PBS-injected mice, and represent the cumulative data from two mice from two independent experiments. The green dashed line represents a threshold of two-fold downregulation and the red dashed line represents a threshold of two-fold upregulation. C57BL/6 (B), MAVS−/− (C), STING−/− (D) and CD11c-Cre × Nemo flox (E) mice were injected i.v. with PBS, 106 TUs IDLV-OVA, OVA/5’ppp-dsRNA or OVA/CpG. Seven days (B-E) or one month (B) later, anti-OVA CTL responses were assessed by an in vivo killing assay (left panels) and IFN-γ ELISPOT (right panels). The results are expressed as the percentage of specific lysis for the in vivo killing assay and IFN-γ SFC per 106 splenocytes for ELISPOT. Each dot represents an individual mouse. The results represent the means ± SEM of cumulative data from 3 to 9 mice from two to three independent experiments (B-D) or 2 to 6 mice from two independent experiments (E). Nemo+ mice were born from the crossing of CD11c-Cre littermate non transgenic mice × Nemo flox mice. In contrast, Nemo− mice were born from the crossing of CD11c-Cre transgenic mice × Nemo flox mice. Statistical analysis was performed by unpaired Student’s t-test in comparison with PBS-treated mice or between control and deficient mice, as indicated by the horizontal bars (ns p > 0.05, * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). See also Figures S7, S8 and S9.

    Article Snippet: Ninety-six-well Multiscreen-HA sterile plates (Millipore, Molsheim, France) were coated with purified anti-IFN-γ mAbs (Murine IFN-γ ELISpot Pair from Diaclone).

    Techniques: Injection, In Vivo, Enzyme-linked Immunospot, Lysis, Transgenic Assay, Mouse Assay